Preclinical Research – Page 2

Species selection questioned during program hold risk review – regulatory deficiency risk analysis

During the preclinical phase, multiple signals can suggest that the species selection may not be appropriate or compliant. Common symptoms include:Click to read the full article.

GLP readiness concerns during regulatory submission prep – regulatory deficiency risk analysis

Identifying symptoms or signals that suggest GLP readiness concerns is the first step in mitigating the risk of regulatory deficiency:Click to read the full article.

Study design not regulator-aligned during study audit – preventing clinical hold

During an audit or routine investigation, several signals may indicate a disconnect between study design and regulatory alignment. Identifying these symptoms early can help prevent potential issues from escalating into…

Study design not regulator-aligned during regulatory submission prep – regulatory deficiency risk analysis

The first step in identifying misalignment in study design is recognizing the symptoms or signals that hint at potential deficiencies. Below are some common indicators in the laboratory or operational…

Study design not regulator-aligned during program hold risk review – FDA/EMA non-clinical expectations

Identifying the signals of study design misalignment is crucial for timely intervention. Symptoms often manifest as unexpected results, deviation reports, or reviewer feedback that highlights deficiencies in study protocols. Here…

Species selection questioned during program hold risk review – CAPA for study design gaps

Investigating Species Selection Questions During Program Hold Risk Reviews In the fast-evolving landscape of pharmaceutical research, one of the critical components of successful drug development is the selection of appropriate…

GLP readiness concerns during sponsor oversight – how to defend preclinical package

When exploring GLP readiness concerns, the initial phase involves identifying observable signals indicative of compliance failures. Symptoms may manifest in various forms, including:Click to read the full article.

Study design not regulator-aligned during regulatory submission prep – how to defend preclinical package

Identifying signals indicating a deviation in study design can be challenging yet essential. Symptoms may manifest in various forms, including:Click to read the full article.

Reproducibility gaps during study audit – how to defend preclinical package

Identifying symptoms indicative of reproducibility gaps is the first step in a thorough investigation. In a laboratory setting, these symptoms may manifest as variations in data that fail to replicate…

Species selection questioned during study audit – preventing clinical hold

Identifying symptoms or signals of inadequate species selection should be the first step in the investigation. Key signals to monitor include:Click to read the full article.

GLP readiness concerns during IND-enabling studies – FDA/EMA non-clinical expectations

Identifying early signals of GLP non-compliance can prevent significant setbacks in the drug development process. Common symptoms in the lab may include:Click to read the full article.

Reproducibility gaps during program hold risk review – CAPA for study design gaps

Detecting reproducibility gaps begins with identifying symptoms that may indicate underlying issues in study design or execution. The following signals are commonly observed in both preclinical studies and program risk…